A key analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) trial (13 752 people with T2DM) found that 1 year of exenatide use, compared with placebo, reduced several inflammatory proteins conventionally associated with AD, including ficolin-2, plasminogen activator inhibitor 1 (PAI-1), soluble vascular cell adhesion protein 1 and a cytokine-cytokine cluster.39 Here, SERPINE1 is linked to type 2 diabetes mellitus.